2004
DOI: 10.1016/j.jpag.2003.11.017
|View full text |Cite
|
Sign up to set email alerts
|

Bone mineral density in adolescent females using depot medroxyprogesterone acetate

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
50
0
3

Year Published

2006
2006
2019
2019

Publication Types

Select...
7
3

Relationship

0
10

Authors

Journals

citations
Cited by 102 publications
(55 citation statements)
references
References 18 publications
(17 reference statements)
1
50
0
3
Order By: Relevance
“…Similar findings in adult patients 104 suggest that weightgain status at 6 months is a strong predictor of future excessive weight gain with ongoing DMPA use but that weight gain on DMPA is not a uniform finding for all patients. 96,98 Because DMPA suppresses circulating estradiol concentrations, it causes lack of BMD accrual [105][106][107] and has an adverse effect on biochemical markers of bone formation and resorption. 108 In response to these concerns, the Food and Drug Administration (FDA) issued a "black-box" warning regarding the risk of decreased BMD among DMPA users in November 2004.…”
Section: Progestin Injectionsmentioning
confidence: 99%
“…Similar findings in adult patients 104 suggest that weightgain status at 6 months is a strong predictor of future excessive weight gain with ongoing DMPA use but that weight gain on DMPA is not a uniform finding for all patients. 96,98 Because DMPA suppresses circulating estradiol concentrations, it causes lack of BMD accrual [105][106][107] and has an adverse effect on biochemical markers of bone formation and resorption. 108 In response to these concerns, the Food and Drug Administration (FDA) issued a "black-box" warning regarding the risk of decreased BMD among DMPA users in November 2004.…”
Section: Progestin Injectionsmentioning
confidence: 99%
“…Studies in both adolescents 77 and adults 78 suggest that weight gain status at 6 months is a strong predictor of future excessive weight gain with ongoing DMPA use, but that weight gain does not occur in all patients. 79,80 DMPA causes reductions in bone mineral density (BMD), [81][82][83] 91 no gynecologic examination is needed to determine eligibility for COC use. Like other combined methods including the contraceptive vaginal ring and transdermal patch, COCs can be started on the same day as the visit ("quick start") in healthy, nonpregnant adolescents.…”
Section: Progestin-only Injectable Contraceptionmentioning
confidence: 99%
“…16 Although depot medroxyprogesterone acetate, an injectable contraceptive, can effectively minimize or eliminate menstrual flow, prolonged use has been linked recently to bone density loss in healthy adolescent females, which may not reverse completely after discontinuation of the medication. 17 Adolescents who are already at risk of osteopenia from chronic medical conditions may be at even greater risk of bone mineral density loss from depot medroxyprogesterone acetate use. Historically, sterilization of minors with developmental disabilities was performed without appropriate regard for their decision-making capacities, abilities to care for children, feelings, or interests.…”
Section: Introductionmentioning
confidence: 99%